Eisler Capital (UK)’s Biogen BIIB Stock Holding History

Eisler Capital (UK)’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.02M	Hold	10,400	–	–	0.01%	442
2024 Q2	$2.41M	Buy	+10,400	New	+$2.26M	0.02%	394
2024 Q1	–	Sell	-16,600	Closed	-$4.3M	–	609
2023 Q4	$4.3M	Sell	16,600 -33,700	-67%	-$8.28M	0.03%	324
2023 Q3	$12.9M	Buy	50,300 +9,200	+22%	+$2.46M	0.08%	188
2023 Q2	$11.7M	Buy	+41,100	New	+$12.2M	0.08%	169
2022 Q3	–	Sell	-50,000	Closed	-$10.2M	–	263
2022 Q2	$10.2M	Hold	50,000	–	–	0.33%	51
2022 Q1	$10.5M	Buy	+50,000	New	+$10.9M	0.18%	136

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eisler Capital (UK)'s BIIB Position: Q3 2024 in Review

Eisler Capital (UK) opened a new position in Biogen (BIIB) in Q3 2024: 3,766 shares worth $730K. The stake represents ﹤0.01% of the portfolio and ranks #509 among its holdings. This is a return to the name: Eisler Capital (UK) previously reported a position in BIIB as recently as Q1 2024.

Eisler Capital (UK) first reported a position in BIIB in Q1 2022 and has held it in 7 quarters since. The position peaked at $8.66M in Q3 2023. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Eisler Capital (UK) held 3,766 shares of Biogen worth $730K as of Q3 2024.
Biogen was a new Eisler Capital (UK) position in Q3 2024.
Biogen made up ﹤0.01% of Eisler Capital (UK)'s portfolio in Q3 2024, its #509 holding.
Eisler Capital (UK) first reported a position in Biogen in Q1 2022 and has held it in 7 quarters since.
Eisler Capital (UK)'s Biogen position peaked at $8.66M in Q3 2023.
916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Eisler Capital (UK)'s 13F filing for Q3 2024, filed 14 Nov 2024.